Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, April 14, 2025 /PRNewswire/ -- ...

Century Therapeutics to host a fireside chat on April 22, discussing iPSC-derived cell therapy programs in autoimmune diseases and cancer. Century Therapeutics, Inc., a biotechnology company ...

In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Century Therapeutics (IPSC – Research Report), with a price target of $2.00. The company’s shares ...

Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price cut by HC Wainwright from $5.00 to $2.00 in a research report report published on Thursday morning,Benzinga reports.

Century Therapeutics, Inc. (NASDAQ: IPSC) announced that its management team will host a live fireside chat on Tuesday, April ...

Guggenheim analyst Kelsey Goodwin lowered the firm’s price target on Century Therapeutics (IPSC) to $5 from $12 and keeps a Buy rating on the shares. Century Therapeutics reported FY24 results ...

Century Therapeutics, Inc. (IPSC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price reduced by Chardan Capital from $11.00 to $7.00 in a research note issued to investors on Monday morning,Benzinga reports.

In the latest quarter, 4 analysts provided ratings for Century Therapeutics IPSC, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their ...

Net loss: US$126.6m (loss narrowed by 7.4% from FY 2023). US$1.61 loss per share (improved from US$2.30 loss in FY 2023). Revenue exceeded analyst estimates by 97%. Earnings per share (EPS) missed ...